Research and development based on the antimicrobial peptide bactericidal mechanism-"cell membrane differentiation mechanism"

Possessing original and independently designed peptide sequences with completely independent intellectual property rights

It has very strong bactericidal advantages against super bacteria MRSA and multi-drug resistant Acinetobacter baumannii containing NDM-1 gene

It was selected as the national 12th and 13th "Five-Year Plan" Mega-Projects for Innovative Drugs of China

Obtained drug clinical trial approval in 2016

Start Phase III clinical trials in 2021

In 2022, it was approved by FDA to carry out phase II clinical trials in the United States

The first peptide suppository in the world, with completely independent intellectual property rights

It has a unique anti bacterial and anti fungal mechanism, and the effect is significant

It is suitable for gynecological infections caused by bacteria and fungi, especially for stubborn infectious diseases caused by drug-resistant strains

In 2017, it was selected as the national "13th Five-Year Plan" Mega-Projects for Innovative Drugs of China

Initiate international clinical trial application in 2021

Human clinical research in Australia will be launched in 2022

Except its significant effect for bacterial and fungi, PL-18 exhibits strong effects against various tumors.Based on the apoptosis and disruptive ability against cancer cell membrane, it is planned to be developed as in-situ injections against breast cancer, skin cancer, cervical cancer and thyroid cancer.

Pre-clinical research phase.

Independent design and development, with completely independent intellectual property rights.Antimicrobial peptide tincture with nano-micro-needles,suitable for various bacterial/fungal epidermal and dermal infections.Fastabsorption, broad antibacterial spectrum, rapid action, no drug resistance.

Pre-clinical research phase.

Independent design and development, with completely independent intellectual property rights.For patients with lung bacterial/fungal infections, especiallysevere lung infections caused by drug-resistant strains.

Pre-clinical research phase.

Newpeptide sequences, high stability in vivo. Broad-spectrum antibacterial activity, especially high activity against resistant strains. For systemic infections, it is planned to be developed as an injection.

Pre-clinical research phase.

A new generation of targeted antiprostate cancer drugs.Excellent stability. Take BKR1 protein as a target to inhibit BKR1 phosphorylation. High safety and low toxicity in vivo. It is planned to be developed as oral and injection preparations.

Pre-clinical research phase.

A new generation of targeted lung/liver anticancer drugs

Excellent stability

Take BKR1 protein as a target to inhibit BKR1 phosphorylation

High safety and low toxicityin vivo

It is planned to be developed as oral and injection preparations

Preclinical research phase